PT  - JOURNAL ARTICLE
AU  - McKeigue, Paul M
AU  - Kennedy, Sharon
AU  - Weir, Amanda
AU  - Bishop, Jen
AU  - McGurnaghan, Stuart J
AU  - McAllister, David
AU  - Robertson, Chris
AU  - Wood, Rachael
AU  - Lone, Nazir
AU  - Murray, Janet
AU  - Caparrotta, Thomas M
AU  - Smith-Palmer, Alison
AU  - Goldberg, David
AU  - McMenamin, Jim
AU  - Ramsay, Colin
AU  - Guthrie, Bruce
AU  - Hutchinson, Sharon
AU  - Colhoun, Helen M
ED  - ,
TI  - Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study
AID  - 10.1101/2020.07.23.20160747
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.23.20160747
4099  - http://medrxiv.org/content/early/2020/07/27/2020.07.23.20160747.short
4100  - http://medrxiv.org/content/early/2020/07/27/2020.07.23.20160747.full
AB  - Objectives To investigate the relation of severe COVID-19 to prior drug prescribing.Design Matched case-control study (REACT-SCOT) based on record linkage to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days.Setting Scottish population.Main outcome measure Severe COVID-19, defined by entry to critical care or fatal outcome.Participants All 4272 cases of severe COVID-19 in Scotland since the start of the epidemic, with 36948 controls matched for age, sex and primary care practice.Results Severe COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in care homes, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.7, 13.2), and was not accounted for by treatment of conditions designated as conferring increased risk. Of 17 drug classes postulated at the start of the epidemic to be “medications compromising COVID”, all were associated with increased risk of severe COVID-19. The largest effect was for antipsychotic agents: rate ratio 4.14 (3.39, 5.07). Other drug classes with large effects included proton pump inhibitors (rate rato 2.19 (1.70, 2.80) for >= 2 defined daily doses/day), opioids (3.62 (2.65, 4.94) for >= 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates, and were stronger with recent than with non-recent exposure.Conclusions Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression or dyskinesia, have anticholinergic effects or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Although the evidence for causality is not conclusive, these results support existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy as a potential means of reducing COVID-19 risk.Registration ENCEPP number EUPAS35558What is already known on this topic Two previous studies have examined the relationship of severe COVID-19 to drugs for the cardiovascular system. This is the first systematic study of the relationship of severe COVID-19 to prior drug prescribing.What this study adds Severe COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression or dyskinesia, have anticholinergic effects or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. These results support earlier warnings that these drug classes that these drugs might increase susceptibility to COVID-19, and reinforce existing guidance on reducing overprescribing of these drug classes.Competing Interest StatementHC receives research support and honoraria and is a member of advisory panels or speaker bureaus for Sanofi Aventis, Regeneron, Novartis, Novo-Nordisk and Eli Lilly. HC receives or has recently received non-binding research support from AstraZeneca and Novo-Nordisk. SH received honoraria from Gilead.Clinical Protocols http://www.encepp.eu/encepp/viewResource.htm?id=35559 Funding StatementThis study was not supported by any external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Public Benefit and Privacy Panel for Health and Social Care, ScotlandAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesApplications for access to the data may be made to the Public Benefit and Privacy Panel for Health and Social Care, Scotland